Epilepsy Archives

Latest Posts

gw pharmaceuticals fda epidiolex cannabinoid epilepsy

News and Trends 26 Jun 2018

Update: The FDA Approves First Cannabinoid Treatment for Epilepsy

Update (26/06/2018): The FDA has approved GW Pharmaceutical's drug Epidiolex in two severe forms of epilepsy. The approval makes Epidolex the first prescription drug made from highly purified cannabidiol to reach…

June 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Feb 2018

GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II

One of GW Pharma's cannabinoid drugs for epilepsy has suffered a set back in a Phase IIa trial as a placebo matched its capacity to reduce the frequency of focal seizures.…

February 22, 2018 - 2 minutesmins - By Alex Dale

News and Trends 12 Jan 2018

This Collaboration Will Develop a New Epilepsy Gene Therapy for In-Need Patients

CombiGene and the Cell and Gene Therapy Catapult have struck a deal that will move the biotech's epilepsy therapy towards the clinic. Swedish biotech CombiGene has combined neuroscience and advances in…

January 12, 2018 - 2 minutesmins - By Alex Dale

News and Trends 15 Dec 2017

Signed, Sealed. Will GW Pharma’s Epilepsy Treatment Be a 2018 Blockbuster?

GW Pharma might be about to join the likes of Genmab in the biotech blockbuster club, with its epilepsy drug predicted to achieve sales of close to $1B in 2018.…

December 15, 2017 - 2 minutesmins - By Alex Dale

More News! 9 Aug 2017

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company's stock price more than 55% -- and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based…

August 9, 2017 - 2 minutesmins - By Evelyn Warner

More News! 29 Mar 2017

More “FDA Love” for Cannabis Company with Orphan Drug Designation

Last year was a doozy for biotech, but it was spectacular for GW Pharmaceuticals. Its streak continues with more special treatment. GW Pharmaceuticals, which is developing epilepsy treatments from marijuana, is making…

March 29, 2017 - 2 minutesmins - By Evelyn Warner

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here's a list of the best success stories of 2016. Biotech is becoming a…

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 21 at 12.29.43 PM e1477045913351

News and Trends 21 Oct 2016

New Partnership comes to the Rescue in Neurological Diseases

Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson's. UCB…

October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2016

World Mental Health Day: How is Biotech Helping the Cause?

Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some…

October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Dec 2016

UPDATE: More Good News on a Cannabis Derivative for Epilepsy

Update (07/12/2017): GW Pharma has announced more positive Phase III results for Epidiolex, pushing the drug closer to the market and a win for supporters of legalizing marijuana. Originally published…

December 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

cannabidiol cannabis epilepsy davet syndrome epidiolex gw pharmaceuticals cbd

News and Trends 26 May 2017

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the…

May 26, 2017 - 4 minutesmins - By Ekaterina Perets

News and Trends 1 Jun 2022

New treatment option available for Dravet syndrome

Global biopharma company UCB says the UK’s National Institute for Healthcare Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for its FINTEPLA (fenfluramine) oral solution. FINTEPLA is used…

June 1, 2022 - 3 minutesmins - By Jim Cornall

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering